Skip to content

NEI Research News

Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.

Source
67 items
National Eye Institute

Avastin as effective as Eylea for treating central retinal vein occlusion

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion (CRVO), according to a clinical trial funded by the National Eye Institute (NEI)...
Grantee News

New Method to Detect Ultrasound with Light

A tiny, transparent device that can fit into a contact lens has a bright future, potentially helping a range of scientific endeavors from biomedicine to geology.
Doctor giving eye exam

Woman who lost vision to diabetes shares experience to raise awareness

It was Labor Day 2015 when Rosetta Ivey-Foster, a 67-year-old retired bank clerk, learned first-hand how quickly diabetes can deteriorate vision.
Dr. Emily Chew of the National Eye Institute examines a patient’s eyes. Photo credit: National Eye Institute.

Eye Study Underscores the Long-lasting Benefits of Controlling Diabetes

People with type 2 diabetes who intensively controlled their blood sugar level were found to have cut their risk of diabetic retinopathy in half.
Grantee News

USC Roski Eye Institute Researchers Publish Largest Eye Study Among Chinese Americans Identifying More Effective Ways to Prevent and Treat Blinding Eye Diseases for This Racial Group

Researchers and clinicians at the University of Southern California Roski Eye Institute have published results of the NEI-funded “Chinese American Eye Study” in JAMA Ophthalmology.
Grantee News

Nerve injury appears to be root of diabetes-related vision loss

Diabetes-related vision loss most often is blamed on blood vessel damage in and around the retina, but new research indicates that much of that vision loss may result from nerve cell injury that occurs long before any blood vessels are damaged.
Patient undergoes and eye exam. Courtesy National Eye Institute.

Eylea Outperforms Avastin for Diabetic Macular Edema with Moderate or Worse Vision Loss

A two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab).
NEI image using a slit lamp

New Treatment Options, Better Hope of Preventing Vision Loss from Diabetes

This National Diabetes Month, there is some good news for people with eye complications from diabetes.
Animation of abnormal blood vessels bleeding into the center of the eye due to proliferative diabetic retinopathy. Photo credit: National Eye Institute. Watch video.

Lucentis Effective for Proliferative Diabetic Retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy.
still from DR eye exam animation

Study Finds Potential New Drug Target for Diabetic Eye Disease

Researchers funded in part by the National Eye Institute (NEI) have identified a protein involved in an advanced stage of diabetic retinopathy, a diabetic eye disease that threatens vision.